Venrock Healthcare Capital Par Acquires 111,111 Shares of Tricida, Inc. (NASDAQ:TCDA) Stock

Tricida, Inc. (NASDAQ:TCDAGet Rating) major shareholder Venrock Healthcare Capital Par acquired 111,111 shares of the company’s stock in a transaction on Wednesday, June 8th. The stock was bought at an average cost of $9.51 per share, with a total value of $1,056,665.61. Following the completion of the acquisition, the insider now directly owns 6,344,084 shares in the company, valued at $60,332,238.84. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

  • On Monday, June 6th, Venrock Healthcare Capital Par acquired 91,506 shares of Tricida stock. The stock was bought at an average cost of $9.35 per share, with a total value of $855,581.10.
  • On Thursday, June 2nd, Venrock Healthcare Capital Par purchased 61,722 shares of Tricida stock. The shares were acquired at an average cost of $8.78 per share, with a total value of $541,919.16.

TCDA traded down $0.50 on Thursday, reaching $8.95. The stock had a trading volume of 386,817 shares, compared to its average volume of 390,770. Tricida, Inc. has a fifty-two week low of $3.55 and a fifty-two week high of $12.45. The firm has a 50-day moving average of $9.40 and a 200-day moving average of $8.99. The company has a current ratio of 5.12, a quick ratio of 5.12 and a debt-to-equity ratio of 584.92. The company has a market capitalization of $496.05 million, a price-to-earnings ratio of -3.10 and a beta of 0.92.

Tricida (NASDAQ:TCDAGet Rating) last issued its earnings results on Tuesday, March 29th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.21). During the same period last year, the business earned ($1.09) earnings per share. Sell-side analysts anticipate that Tricida, Inc. will post -2.2 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently modified their holdings of TCDA. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Tricida by 92.2% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,270 shares of the company’s stock worth $27,000 after purchasing an additional 1,569 shares in the last quarter. Dorsey Wright & Associates acquired a new position in Tricida in the 1st quarter worth about $30,000. Quantbot Technologies LP bought a new stake in shares of Tricida in the 1st quarter valued at about $45,000. Hsbc Holdings PLC bought a new stake in shares of Tricida in the 3rd quarter valued at about $47,000. Finally, Royal Bank of Canada bought a new stake in shares of Tricida in the 1st quarter valued at about $55,000. 79.28% of the stock is owned by institutional investors and hedge funds.

A number of research firms have recently commented on TCDA. Needham & Company LLC reissued a “buy” rating and set a $18.00 price target (down previously from $20.00) on shares of Tricida in a report on Wednesday, March 30th. The Goldman Sachs Group lowered their price target on Tricida from $22.00 to $16.00 and set a “buy” rating for the company in a report on Tuesday, May 24th.

About Tricida (Get Rating)

Tricida, Inc operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track.

See Also

Insider Buying and Selling by Quarter for Tricida (NASDAQ:TCDA)

Want More Great Investing Ideas?

Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with MarketBeat.com's FREE daily email newsletter.